{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:07:07Z","timestamp":1793830027451,"version":"4.6.1"},"reference-count":127,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1584,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA: A Cancer Journal for Clinicians"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.3322\/caac.20103","type":"journal-article","created":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T03:24:31Z","timestamp":1304565871000},"page":"139-156","source":"Crossref","is-referenced-by-count":57,"title":["Aging and osteoporosis in breast and prostate cancer"],"prefix":"10.1002","volume":"61","author":[{"given":"Ari","family":"VanderWalde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Hurria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,4]]},"reference":[{"key":"10.3322\/caac.20103-BIB1|cit1","volume-title":"SEER Cancer Statistics Review, 1975-2007","author":"Altekruse","year":"2010"},{"issue":"Suppl 1","key":"10.3322\/caac.20103-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.3747\/co.2008.174","article-title":"Cancer treatment-related bone loss: a review and synthesis of the literature","volume":"15","author":"Khan","year":"2008","journal-title":"Curr Oncol."},{"key":"10.3322\/caac.20103-BIB3|cit3","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1200\/JCO.2008.17.7451","article-title":"Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis","volume":"26","author":"Camacho","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB4|cit4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1749-6632.1998.tb09914.x","article-title":"Nutrition, osteoporosis, and aging","volume":"854","author":"Nordin","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"10.3322\/caac.20103-BIB5|cit5","volume-title":"Osteoporosis in the European Community: A Call to Action-An Audit of Policy Developments Since 1998","author":"International Osteoporosis Foundation","year":"2003"},{"key":"10.3322\/caac.20103-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet."},{"key":"10.3322\/caac.20103-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2105\/AJPH.82.8.1147","article-title":"Race and sex differences in mortality following fracture of the hip","volume":"82","author":"Jacobsen","year":"1992","journal-title":"Am J Public Health."},{"key":"10.3322\/caac.20103-BIB8|cit8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jbspin.2009.10.001","article-title":"Osteoporosis in males and females: is there really a difference?","volume":"76","author":"Guggenbuhl","year":"2009","journal-title":"Joint Bone Spine."},{"key":"10.3322\/caac.20103-BIB9|cit9","first-page":"244","article-title":"Rehabilitation after falls and fractures","volume":"8","author":"Dionyssiotis","year":"2008","journal-title":"J Musculoskelet Neuronal Interact."},{"key":"10.3322\/caac.20103-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB11|cit11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1148\/radiology.202.2.9015088","article-title":"Methotrexate osteopathy in patients with osteosarcoma","volume":"202","author":"Ecklund","year":"1997","journal-title":"Radiology."},{"key":"10.3322\/caac.20103-BIB12|cit12","first-page":"67","article-title":"Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells","volume":"28","author":"Glackin","year":"1992","journal-title":"Biochem Int."},{"key":"10.3322\/caac.20103-BIB13|cit13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02546226","article-title":"Chemical and morphologic alterations of rabbit bone induced by adriamycin","volume":"18","author":"Young","year":"1975","journal-title":"Calcif Tissue Res."},{"key":"10.3322\/caac.20103-BIB14|cit14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000146262","article-title":"Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide","volume":"127","author":"Wang","year":"1986","journal-title":"Acta Anat (Basel)."},{"key":"10.3322\/caac.20103-BIB15|cit15","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1210\/jc.81.10.3441","article-title":"Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis","volume":"81","author":"Canalis","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"10.3322\/caac.20103-BIB16|cit16","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1542\/peds.2007-1396","article-title":"Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature","volume":"121","author":"Wasilewski-Masker","year":"2008","journal-title":"Pediatrics."},{"key":"10.3322\/caac.20103-BIB17|cit17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/eje.0.1370209","article-title":"Glucocorticoid osteoporosis-mechanisms and management","volume":"137","author":"Reid","year":"1997","journal-title":"Eur J Endocrinol."},{"key":"10.3322\/caac.20103-BIB18|cit18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hon.2900100308","article-title":"Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause","volume":"10","author":"Ratcliffe","year":"1992","journal-title":"Hematol Oncol."},{"key":"10.3322\/caac.20103-BIB19|cit19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","article-title":"Premature menopause or early menopause: long-term health consequences","volume":"65","author":"Shuster","year":"2009","journal-title":"Maturitas."},{"key":"10.3322\/caac.20103-BIB20|cit20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/gme.0b013e31804c793d","article-title":"Effect of early menopause on bone mineral density and fractures","volume":"14","author":"Gallagher","year":"2007","journal-title":"Menopause."},{"key":"10.3322\/caac.20103-BIB21|cit21","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer","volume":"26","author":"Saad","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB22|cit22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0890-6238(90)90060-9","article-title":"Vinblastine reduces progesterone and prostaglandin E production by rat granulosa cells in vitro","volume":"4","author":"Teaff","year":"1990","journal-title":"Reprod Toxicol."},{"key":"10.3322\/caac.20103-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/bjc.1996.213","article-title":"Endocrinological late effects after chemotherapy for testicular cancer","volume":"73","author":"Berger","year":"1996","journal-title":"Br J Cancer."},{"issue":"3 pt 1","key":"10.3322\/caac.20103-BIB24|cit24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0022-5347(01)64333-7","article-title":"Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer","volume":"158","author":"Brennemann","year":"1997","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.3322\/caac.20103-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0895-4356(96)00211-9","article-title":"Fracture risk following bilateral oophorectomy","volume":"49","author":"Melton","year":"1996","journal-title":"J Clin Epidemiol."},{"key":"10.3322\/caac.20103-BIB27|cit27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1359\/jbmr.2003.18.5.900","article-title":"Fracture risk after bilateral oophorectomy in elderly women","volume":"18","author":"Melton","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.3322\/caac.20103-BIB28|cit28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1359\/JBMR.041220","article-title":"Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women","volume":"20","author":"Antoniucci","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"suppl 1","key":"10.3322\/caac.20103-BIB29|cit29","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev."},{"key":"10.3322\/caac.20103-BIB30|cit30","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1994.12.5.992","article-title":"Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study","volume":"12","author":"Kristensen","year":"1994","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB31|cit31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0169-6009(08)80220-6","article-title":"Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postemenopausal women","volume":"22","author":"Ward","year":"1993","journal-title":"Bone Miner."},{"key":"10.3322\/caac.20103-BIB32|cit32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB33|cit33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB34|cit34","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2007.15.7123","article-title":"Tamoxifen use and osteoporotic fracture risk: a population-based analysis","volume":"26","author":"Cooke","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079907X187919","article-title":"Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer","volume":"23","author":"Bell","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"10.3322\/caac.20103-BIB36|cit36","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-04-0438","article-title":"Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats","volume":"10","author":"Goss","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.3322\/caac.20103-BIB37|cit37","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.3322\/caac.20103-BIB38|cit38","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ejca.2007.08.029","article-title":"Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women","volume":"41","author":"McCloskey","year":"2007","journal-title":"Eur J Cancer."},{"key":"10.3322\/caac.20103-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB40|cit40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.3322\/caac.20103-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res."},{"key":"10.3322\/caac.20103-BIB42|cit42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med."},{"key":"10.3322\/caac.20103-BIB44|cit44","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB45|cit45","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","article-title":"Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study","volume":"42","author":"Geisler","year":"2006","journal-title":"Eur J Cancer."},{"key":"10.3322\/caac.20103-BIB46|cit46","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer","volume":"23","author":"Lonning","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB47|cit47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet."},{"key":"10.3322\/caac.20103-BIB48|cit48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.3322\/caac.20103-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdn762","article-title":"Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy","volume":"20","author":"Hadji","year":"2009","journal-title":"Ann Oncol."},{"key":"10.3322\/caac.20103-BIB50|cit50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3816\/CBC.2008.n.065","article-title":"The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer","volume":"8","author":"Jones","year":"2008","journal-title":"Clin Breast Cancer."},{"key":"10.3322\/caac.20103-BIB51|cit51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3816\/CBC.2006.n.021","article-title":"Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors","volume":"7","author":"Mincey","year":"2006","journal-title":"Clin Breast Cancer."},{"key":"10.3322\/caac.20103-BIB52|cit52","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/jc.2009-0739","article-title":"Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels","volume":"94","author":"Burnett-Bowie","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.3322\/caac.20103-BIB53|cit53","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA."},{"key":"10.3322\/caac.20103-BIB54|cit54","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1200\/JCO.2007.11.1559","article-title":"Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review","volume":"25","author":"Antonarakis","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB56|cit56","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone-na\u00efve men with prostate carcinoma","volume":"91","author":"Smith","year":"2001","journal-title":"Cancer."},{"key":"10.3322\/caac.20103-BIB57|cit57","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1464-410X.2007.07163.x","article-title":"Fracture risk in Danish men with prostate cancer: a nationwide register study","volume":"100","author":"Abrahamsen","year":"2007","journal-title":"BJU Int."},{"key":"10.3322\/caac.20103-BIB58|cit58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med."},{"key":"10.3322\/caac.20103-BIB59|cit59","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB60|cit60","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ju.0000143930.73016.c6","article-title":"Hip fractures in men with prostate cancer treated with orchiectomy","volume":"172","author":"Dickman","year":"2004","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB61|cit61","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.87.8.3656","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.3322\/caac.20103-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","article-title":"Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression","volume":"175","author":"Morote","year":"2006","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB63|cit63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.urology.2004.03.012","article-title":"Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer","volume":"64","author":"Miyaji","year":"2004","journal-title":"Urology."},{"key":"10.3322\/caac.20103-BIB64|cit64","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","article-title":"Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss","volume":"5","author":"Preston","year":"2002","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.3322\/caac.20103-BIB65|cit65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB66|cit66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer."},{"key":"10.3322\/caac.20103-BIB67|cit67","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.3322\/caac.20103-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB69|cit69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","article-title":"Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid","volume":"100","author":"Ryan","year":"2007","journal-title":"BJU Int."},{"key":"10.3322\/caac.20103-BIB70|cit70","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB71|cit71","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB72|cit72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST Study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer."},{"key":"10.3322\/caac.20103-BIB73|cit73","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer."},{"key":"10.3322\/caac.20103-BIB75|cit75","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat."},{"key":"10.3322\/caac.20103-BIB76|cit76","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone."},{"key":"10.3322\/caac.20103-BIB77|cit77","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB78|cit78","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr2565","article-title":"Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial","volume":"12","author":"Markopoulos","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.3322\/caac.20103-BIB79|cit79","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB80|cit80","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res."},{"key":"10.3322\/caac.20103-BIB81|cit81","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.hoc.2007.03.004","article-title":"Bisphosphonates for breast cancer: questions answered, questions remaining","volume":"21","author":"Layman","year":"2007","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.3322\/caac.20103-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ijc.20826","article-title":"Skeletal health in postmenopausal survivors of early breast cancer","volume":"114","author":"Mackey","year":"2005","journal-title":"Int J Cancer."},{"key":"10.3322\/caac.20103-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostate cancer-a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.3322\/caac.20103-BIB84|cit84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jneb.2007.08.009","article-title":"Are cancer survivors\/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions","volume":"40","author":"McKean","year":"2008","journal-title":"J Nutr Educ Behav."},{"key":"10.3322\/caac.20103-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res."},{"key":"10.3322\/caac.20103-BIB86|cit86","volume-title":"WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level; Summary Meeting Report, Brussels, Belgium, 5-7 May 2004","author":"World Health Organization","year":"2007"},{"key":"10.3322\/caac.20103-BIB87|cit87","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-137-6-200209170-00014","article-title":"Screening for osteoporosis in postmenopausal women: recommendations and rationale","volume":"137","author":"U.S. Preventive Services Task Force","year":"2002","journal-title":"Ann Intern Med."},{"key":"10.3322\/caac.20103-BIB88|cit88","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-148-9-200805060-00008","article-title":"Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians","volume":"148","author":"Qaseem","year":"2008","journal-title":"Ann Intern Med."},{"key":"10.3322\/caac.20103-BIB89|cit89","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-137-6-200209170-00015","article-title":"Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force","volume":"137","author":"Nelson","year":"2002","journal-title":"Ann Intern Med."},{"key":"10.3322\/caac.20103-BIB90|cit90","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7326\/0003-4819-153-2-201007200-00262","article-title":"Screening for osteoporosis: an update for the U.S. Preventive Services Task Force","volume":"153","author":"Nelson","year":"2010","journal-title":"Ann Intern Med."},{"key":"10.3322\/caac.20103-BIB91|cit91","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jbmr.5650080507","article-title":"Effects of weight and body mass index on bone mineral density in men and women: the Framingham study","volume":"8","author":"Felson","year":"1993","journal-title":"J Bone Miner Res."},{"issue":"3 suppl","key":"10.3322\/caac.20103-BIB92|cit92","doi-asserted-by":"crossref","first-page":"433S","DOI":"10.1093\/ajcn\/63.3.433","article-title":"Putting body weight and osteoporosis into perspective","volume":"63","author":"Wardlaw","year":"1996","journal-title":"Am J Clin Nutr."},{"key":"10.3322\/caac.20103-BIB93|cit93","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.3322\/caac.20103-BIB94|cit94","unstructured":"World Health Organization Collaborating Centre for Metabolic Bone Diseases www.shef.ac.uk\/FRAX\/"},{"key":"10.3322\/caac.20103-BIB95|cit95","first-page":"935","article-title":"Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis","volume":"155","author":"Murray","year":"1996","journal-title":"CMAJ."},{"key":"10.3322\/caac.20103-BIB96|cit96","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5694\/j.1326-5377.2009.tb02421.x","article-title":"Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia","volume":"190","author":"Sanders","year":"2009","journal-title":"Med J Aust."},{"issue":"suppl 3","key":"10.3322\/caac.20103-BIB97|cit97","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","article-title":"NCCN Task Force Report: Bone Health in Cancer Care","volume":"7","author":"Gralow","year":"2009","journal-title":"J Natl Compr Canc Netw."},{"key":"10.3322\/caac.20103-BIB98|cit98","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1079\/PHN2001140","article-title":"Calcium and vitamin D nutrition and bone disease of the elderly","volume":"4","author":"Gennari","year":"2001","journal-title":"Public Health Nutr."},{"key":"10.3322\/caac.20103-BIB99|cit99","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0163-7258(02)00164-X","article-title":"Role of Ca(2+) and vitamin D in the prevention and treatment of osteoporosis","volume":"93","author":"Rodriguez-Martinez","year":"2002","journal-title":"Pharmacol Ther."},{"key":"10.3322\/caac.20103-BIB100|cit100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","article-title":"Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years or older: a meta-analysis","volume":"370","author":"Tang","year":"2007","journal-title":"Lancet."},{"key":"10.3322\/caac.20103-BIB101|cit101","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med."},{"key":"10.3322\/caac.20103-BIB102|cit102","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.amjmed.2006.02.038","article-title":"Randomized controlled trial of calcium in healthy older women","volume":"119","author":"Reid","year":"2006","journal-title":"Am J Med."},{"key":"10.3322\/caac.20103-BIB103|cit103","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA."},{"key":"10.3322\/caac.20103-BIB104|cit104","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00198-007-0501-2","article-title":"Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study","volume":"19","author":"Nieves","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.3322\/caac.20103-BIB105|cit105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.maturitas.2010.03.012","article-title":"Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer","volume":"66","author":"Nogues","year":"2010","journal-title":"Maturitas."},{"key":"10.3322\/caac.20103-BIB106|cit106","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol."},{"key":"10.3322\/caac.20103-BIB107|cit107","first-page":"CD000333","article-title":"Exercise for preventing and treating osteoporosis in postmenopausal women","volume":"(3)","author":"Bonaiuti","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"key":"10.3322\/caac.20103-BIB108|cit108","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00198-008-0776-y","article-title":"Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial","volume":"20","author":"Kukuljan","year":"2009","journal-title":"Osteoporos Int."},{"key":"10.3322\/caac.20103-BIB109|cit109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1741-7015-8-47","article-title":"Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life","volume":"8","author":"Nikander","year":"2010","journal-title":"BMC Med."},{"key":"10.3322\/caac.20103-BIB110|cit110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/mi.10.3.5","article-title":"Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition","volume":"10","author":"Drake","year":"2010","journal-title":"Mol Interv."},{"key":"10.3322\/caac.20103-BIB111|cit111","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/BOR.0b013e32833ad677","article-title":"Bisphosphonate adverse effects, lessons from large databases","volume":"22","author":"Abrahamsen","year":"2010","journal-title":"Curr Opin Rheumatol."},{"key":"10.3322\/caac.20103-BIB112|cit112","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med."},{"key":"10.3322\/caac.20103-BIB113|cit113","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet."},{"key":"10.3322\/caac.20103-BIB114|cit114","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1258\/136218005775544273","article-title":"Is there a role for hormone replacement therapy after breast cancer?","volume":"11","author":"Kwan","year":"2005","journal-title":"J Br Menopause Soc."},{"key":"10.3322\/caac.20103-BIB115|cit115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J Natl Cancer Inst."},{"key":"10.3322\/caac.20103-BIB116|cit116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA."},{"issue":"6 pt 1","key":"10.3322\/caac.20103-BIB117|cit117","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","article-title":"Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer","volume":"171","author":"Sieber","year":"2004","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB118|cit118","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00345-003-0322-7","article-title":"The non-steroidal antiandrogen, bicalutamide (\u2018Casodex\u2019), may preserve bone mineral density as compared with castration: results of a preliminary study","volume":"21","author":"Tyrrell","year":"2003","journal-title":"World J Urol."},{"key":"10.3322\/caac.20103-BIB119|cit119","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J Natl Compr Canc Netw."},{"key":"10.3322\/caac.20103-BIB120|cit120","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.urology.2004.07.019","article-title":"Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression","volume":"64","author":"Higano","year":"2004","journal-title":"Urology."},{"key":"10.3322\/caac.20103-BIB121|cit121","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology."},{"key":"10.3322\/caac.20103-BIB122|cit122","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.3322\/caac.20103-BIB123|cit123","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol."},{"key":"10.3322\/caac.20103-BIB124|cit124","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.3322\/caac.20103-BIB125|cit125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat."},{"key":"10.3322\/caac.20103-BIB126|cit126","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med."},{"key":"10.3322\/caac.20103-BIB127|cit127","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol."}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.20103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.3322\/caac.20103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T21:41:15Z","timestamp":1592516475000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.3322\/caac.20103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.3322\/caac.20103","relation":{},"ISSN":["0007-9235"],"issn-type":[{"value":"0007-9235","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}